Morgan Stanley rated Overweight Akebia Therapeutics Inc. (NASDAQ: AKBA) on 09/09/2015, when the stock price was $11.96. Since then, Akebia Therapeutics Inc. has lost 45.90% as of 12/15/2015's recent price of $6.47.
If you would have followed this Morgan Stanley's recommendation on AKBA, you would have lost 45.9% of your investment in 97 days.



Morgan Stanley Investment Research is one of the financial industry's dominant thought leaders in equity and fixed-income investing. Our analysts, economists, and strategists have earned this reputation through timely, in-depth analysis of companies, industries, markets, and the world’s economies. Our teams collaborate to assist Morgan Stanley clients with investment decisions, using cash and derivative instruments across major asset classes and geographies.

Marked as spam